All In Biotech

Drug Trial Radar · NCT06751524

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Botensilimab and Balstilimab Expanded Access Program

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Dec 30, 2024

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

  • Colorectal Cancer (CRC)
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Hepatocellular Carcinoma (HCC)
  • Melanoma
  • Sarcoma
  • Ovarian Cancer
  • Prostate Cancer

Interventions

  • BotensilimabDrug

    Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).

  • BalstililmabDrug

    Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.